GLAUKOS Corp
Close on Oct 19, 2026
- Market cap
- $9.82B
- P/E (TTM)
- –
- Dividend yield
- –
About Glaukos
Surgical & Medical Instruments & Apparatus, SIC 3841
Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of therapies for glaucoma, corneal disorders, and retinal diseases. Its product portfolio and pipeline include micro-invasive glaucoma surgery devices such as iStent, iStent inject W, and iStent infinite, sustained-release pharmaceuticals including iDose TR, and corneal health treatments such as Photrexa and Epioxa. The company operates in key therapeutic areas centered on glaucoma and corneal health, serving ophthalmic surgeons and specialized eye care professionals.
The company conducts business domestically within the United States and across international markets, with operations and regulatory activities spanning countries such as the United Kingdom, Germany, France, and Japan. Glaukos operates facilities in locations including Burlington, Massachusetts, and Aliso Viejo, California, with its principal executive offices and global headquarters situated in Aliso Viejo, California.
Summary of the business section of Glaukos's latest annual report, written by StockData.
Company profile
Company
- Legal name
- GLAUKOS Corp
- Headquarters
- Aliso Viejo, CA
- Address
- 1 Glaukos Way 92656
- Phone
- (949) 367-9600
- Website
- glaukos.com
- Employees
- 1,094, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Irvine, California
Stock & identifiers
- Ticker
- GKOS
- Exchange
- NYSE
- IPO date
- Jun 25, 2015
- Shares outstanding
- 59M, Jul 28, 2026
- Public float
- $5.91B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1192448
- CUSIP
- 377322102
- ISIN
- US3773221029
- LEI
- 5299004JA1LHE21M6T14
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Thomas William Burns | CHAIRMAN & CEO, Director | 1,768,667 |
| Tomas Navratil | CHIEF DEVELOPMENT OFFICER | 70,818 |
| Joseph E. Gilliam | PRESIDENT & COO | 132,588 |
| Alex R. Thurman | SVP & CHIEF FINANCIAL OFFICER | 63,906 |
| Gilbert H. Kliman | Director | 42,608 |
| Leana Wen | Director | 21,092 |
| Denice Torres | Director | 24,212 |
| David F. Hoffmeister | Director | 87,725 |
| Marc Stapley | Director | 39,327 |
| Aimee S. Weisner | Director | 52,189 |
| Mark J. Foley | Director | 60,267 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Thomas W. Burns | $12.03M | $9.99M | $4.71M | $150 | $78 |
| FY2024 Thomas W. Burns | $9.03M | $25.16M | $3.13M | $199 | $78 |
| FY2023 Thomas W. Burns | $8.65M | $22.35M | $3.04M | $106 | $76 |
| FY2022 Thomas W. Burns | $6.27M | $5.46M | $2.93M | $58 | $78 |
| FY2021 Thomas W. Burns | $7.26M | -$172.51K | $2.20M | $59 | $106 |
| FY2020 Thomas W. Burns | $6.02M | $11.77M | $2.16M | $138 | $131 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 1,094 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 21, 2019 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Sep 17, 2019 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Apr 12, 2017 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jun 30, 2015 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jun 25, 2015 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 22, 2015 | Listing | Registration of securities on an exchange (Form 8-A) |